Welcome to our dedicated page for YD Bio SEC filings (Ticker: YDES), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
YD Bio Limited (NASDAQ: YDES) files reports with the U.S. Securities and Exchange Commission as a foreign private issuer, providing investors with detailed information on its biotechnology operations, governance, and capital markets activities. On this page, you can review YD Bio’s SEC filings, including Form 6‑K current reports that describe significant corporate events and financial disclosures related to its DNA methylation‑based cancer detection technology, ophthalmologic innovations, and clinical‑trial supply business.
Recent Form 6‑K filings referenced by the company include unaudited interim financial statements and management’s discussion and analysis for YD Bio and its subsidiary YD Biopharma, pro forma financial information following its business combination with Breeze Holdings Acquisition Corp., and press releases furnished as exhibits. Other 6‑K reports detail changes in the company’s independent registered public accounting firm, including the termination of CBIZ CPAs P.C. and the engagement of ARK Pro CPA & Co, as well as the resignation and appointment of audit committee leadership and notices related to Nasdaq director independence requirements.
Investors can also use YD Bio’s filings to track matters such as registration statements affecting the exercisability of publicly traded warrants (YDESW), disclosures about going‑concern explanatory paragraphs in prior audit reports, and information on how the company structures its reporting as a foreign private issuer under Form 20‑F. These documents help explain how YD Bio manages financial reporting, auditor relationships, and board composition while it advances programs in oncology diagnostics and limbal stem cell and exosome therapies.
Stock Titan’s SEC filings page for YDES is designed to surface these regulatory documents quickly, alongside AI‑powered summaries that highlight key points such as changes in auditors, governance updates, and links between financial disclosures and the company’s stated strategy. Users can review Form 6‑K exhibits, interim financials, and other submitted materials to better understand YD Bio’s risk factors, capital structure, and operational priorities.
YD Bio Ltd files an amended Schedule 13G showing beneficial ownership stakes. The filing reports that Ethan Shen beneficially owns 54,345,011 ordinary shares (77.06%) and YD Biopharma Holding Limited beneficially owns 43,120,858 ordinary shares (61.15%). The filing states these percentages are calculated from a total of 70,521,359 ordinary shares as of November 17, 2025, per the issuer's Rule 424(b)(3) prospectus. The cover-page rows break ownership into sole and shared voting and dispositive powers, with Mr. Shen holding 11,224,153 sole voting and dispositive shares and 43,120,858 shared voting and dispositive shares through the Cayman Islands entity.
YD Bio Limited filed a prospectus supplement tied to its Form F-1, covering 11,500,000 ordinary shares issuable on exercise of public warrants, 59,136,934 ordinary shares offered by selling shareholders, and 5,425,000 ordinary shares issuable upon exercise of additional warrants. The supplement attaches a Form 6-K describing a binding letter of intent to acquire Safe Save Medical Cell Sciences & Technology (SSMC) through a new holding company for total consideration of NT$839,832,000 (approximately US$26.87 million) paid in a mix of cash and newly issued YD Bio shares. Large SSMC shareholders will receive YD Bio shares via share swap, while others can choose cash or shares, all subject to six‑month or one‑year lock‑ups. Closing depends on due diligence, SSMC’s restructuring and no material adverse change, with diligence targeted by March 20, 2026 and closing about 30 days later, after which YD Bio would indirectly own all of SSMC’s business and assets.
YD Bio Limited has entered into a binding letter of intent to acquire Safe Save Medical Cell Sciences & Technology Co., Ltd. (“SSMC”), a Taiwan-based dendritic cell immunotherapy platform. The deal is structured through a new offshore holding entity, Safe Save Cell (KY) Holdings Limited, which will hold 100% of SSMC’s equity.
The total consideration is expected to be NT$839,832,000 (approximately US$26.87 million), paid in a mix of cash and newly issued YD Bio ordinary shares. Large SSMC shareholders, including the founder and affiliates, will receive YD Bio shares via share swap, while other shareholders may choose cash or shares. New shares will be locked up for six months for general shareholders and one year for specific shareholders.
Closing is subject to due diligence, SSMC’s restructuring, and no material adverse change, with due diligence targeted by March 20, 2026 and closing expected within 30 days thereafter. After completion, YD Bio expects to own all of SSMC’s shares, business, and assets, strengthening its position in advanced immunocell and cancer therapies.
YD Bio Limited reports governance changes and a listing status update. On January 16, 2026, the Board appointed Dr. Chang as Chairman of the Compensation Committee and as a member of the Audit Committee and the Nominating and Corporate Governance Committee. On the same date, Dr. Lu was appointed Chairman of the Nominating and Corporate Governance Committee and as a member of the Audit Committee and Compensation Committee.
The company states that Dr. Chang and Dr. Lu have no material related-party interests, arrangements, or family relationships requiring disclosure under specified SEC regulations. On January 20, 2026, YD Bio notified Nasdaq that it has regained compliance with Audit Committee requirements under Nasdaq Listing Rule 5605 and is no longer in a cure period under Listing Rule 5605(c)(4)(B).
YD Bio Limited reported significant changes to its Board of Directors initiated by its majority shareholders. YD Biopharma Holding Limited and EG Biomed Limited, whose combined holdings represent a majority of the company’s voting rights, delivered a shareholders’ written consent removing four directors and appointing two new ones, effective December 30, 2025. Former directors Joe Douglas Ramsey, Albert Scott McLelland, Michaela Ann Griggs and Janet Hall were removed, while Dr. Kochi Chang and Dr. Shao-Da Lu joined the Board. Both new directors bring long-standing medical and healthcare-related leadership experience, including clinical practice, association leadership and medical device industry roles.
YD Bio Limited furnished an investor presentation outlining its plan to build an integrated biotechnology ecosystem and sharing recent financial performance.
Net revenue increased by $160,229 thousand, or 46%, from $350,131 thousand for the year ended December 31, 2023 to $510,360 thousand for the year ended December 31, 2024. In 2024, medical and related products contributed 57.4% of revenue, drugs 28.1%, nutritional products 8.2%, and supplements 6.3%.
Gross profit was $153,445 thousand in 2023 and $155,356 thousand in 2024. The presentation describes four main platforms in regulated diagnostics, ocular health commercialization, life science distribution, and wellness, along with planned U.S.-anchored operations, clinical trial services, manufacturing, and selective M&A to support a long-term, partner-driven growth model.
YD Bio Limited reported a change in its independent auditor. On December 24, 2025, the board’s audit committee dismissed ARK Pro CPA & Co as the company’s independent registered public accounting firm and, effective the same day, approved MaloneBailey, LLP as the new auditor. ARK Pro had been appointed only in September 2025 for the fiscal year ending December 31, 2025.
The company states that from September 17, 2025 through December 24, 2025, it had no disagreements with ARK Pro on accounting principles, financial statement disclosure, or audit scope and procedures that would have required mention in ARK Pro’s reports. ARK Pro provided a letter to the SEC agreeing with the company’s description of its relationship with the firm in the first three paragraphs of the disclosure.
YD Bio Limited has filed a prospectus covering a mixed offering linked to its recent business combination with Breeze Holdings. The company is registering up to 11,500,000 Ordinary Shares issuable upon exercise of Public Warrants at an exercise price of $11.50 per share, and registering for resale 59,136,934 existing Ordinary Shares plus 5,425,000 Ordinary Shares issuable upon exercise of Private Warrants held by selling shareholders.
YD Bio will not sell shares directly in this offering and will not receive proceeds from shareholder resales. It would receive up to $132,250,000 from full cash exercise of the Public Warrants and up to $62,387,500 from full cash exercise of the Private Warrants, but the Warrants may expire unexercised. As of November 14, 2025, 70,521,359 Ordinary Shares were outstanding, rising to 87,437,359 if all registered Warrants are exercised. The shares trade on Nasdaq’s Global Market under the symbol YDES, and the prospectus highlights that investing in these securities involves a high degree of risk.
YD Bio Limited reported changes to its board and audit committee. On October 27, 2025, the board accepted the resignation of independent director and Audit Committee chair Joseph Hing Lung Tseng, who left purely for personal reasons and not due to any disagreement with the company. On November 13, 2025, the board appointed Jerry Yin-Chia Lee as an independent director and new Audit Committee chair. Mr. Lee is an experienced finance professional and founder of Gravity Capital Investment Company, with extensive board roles in biotech and healthcare companies. The company also disclosed that Jan Hall no longer qualifies as an independent director, and under Nasdaq Listing Rule 5605(c)(4)(B) the company has 180 days from the notice date to regain compliance with Nasdaq’s audit committee independence requirements.
YD Bio Limited filed Amendment No. 1 to its Form F-1. The filing registers the issuance of up to 11,500,000 ordinary shares upon exercise of Public Warrants and the resale of up to 59,136,934 ordinary shares plus 5,425,000 shares issuable upon exercise of Private Warrants by selling shareholders. The company is not selling securities in this prospectus.
YD Bio will not receive proceeds from shareholder resales; it would receive cash only if warrants are exercised, including $132,250,000 from Public Warrants and $62,387,500 from Private Warrants if fully exercised in cash. Ordinary shares outstanding were 70,521,359 as of October 22, 2025; assuming full warrant exercises, outstanding shares would be 87,437,359.
The business focuses on blood-based cancer detection and stem cell/exosome therapeutics. Key risks include heavy reliance on licenses from EG BioMed and 3D Global (with royalties and milestones), regulatory uncertainty for lab‑developed tests, customer concentration (Alcon and Novartis ~55% of 2024 revenue), manufacturing dependence on third parties, and potential HFCAA/PCAOB audit inspection constraints. Ordinary shares trade on Nasdaq as “YDES.”